

# Autonomic Dysfunction in Parkinson Disease and Other Neurological Disorders

Aristide Merola, MD, PhD

Associate Professor, Neurology
Center for Parkinson Disease and other Movement Disorders
The Ohio State University Wexner Medical Center
Columbus, USA



#### **Disclosures**

#### **Speaker Honoraria and Consultancies**


- Abbott Laboratories
- Abbvie
- Medtronic
- Theravance BioPharma

#### **Grant Support**

- NIH
- Lundbeck
- Abbvie



#### **The Autonomic Nervous System**





The Nondeclaration of Nonmotor Symptoms of Parkinson's Disease to Health Care Professionals: An International Study Using the Nonmotor Symptoms Questionnaire

#### Multicenter International Study (13 Centers)

242 PD patients were asked to fill in the NMSQ

After completion they were asked if they had discussed the positive symptoms with any Health Care Professional before




# The Nondeclaration of Nonmotor Symptoms of Parkinson's Disease to Health Care Professionals: An International Study Using the Nonmotor Symptoms Questionnaire

Symptom	Positive	Non-declared
Dribbling	41.7%	45.5%
Constipation	47.5%	46.1%
Urinary Urgency	59.9%	42.1%
Dizziness	38.8%	50.0%
Sweating	30.6%	33.8%



Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?

121 consecutive PD patients:



#### Pre-Motor PD (n= 40):

SN hyperecogenicity + hyposmia + depression + mild motor alterations suggestive of extrapyramidal involvement

#### **Compared to:**

- a) Healthy Controls
- b) PD patients

$$(n=50)$$

$$(n=113)$$



	Healthy Controls	Pre-Motor PD	PD
Urinary Dysfunction	6%	18%	44%
Bowel Dysfunction	4%	11%	34%
Sexual Dysfunction	12%	15%	35%
ОН	0%	7.5%	28.1%




	Healthy Controls	Pre-Motor PD	PD
Urinary Dysfunction	6%	18%	44%
Bowel Dysfunction	4%	11%	34%
Sexual Dysfunction	12%	15%	35%
ОН	0%	7.5%	28.1%




	Healthy Controls	Pre-Motor PD	PD
Urinary Dysfunction	6%	18%	44%
Bowel Dysfunction	4%	11%	34%
Sexual Dysfunction	12%	15%	35%
ОН	0%	7.5%	28.1%

#### **OH Prevalence in Parkinson Disease**



#### **Tilt Table Testing**







The table is tilted up laying → > 60° for 5 minutes while recording BP and HR




Lay down for 5 minutes while recording BP and HR



#### **Head-up Tilt: Normal BP Response**

- 1) Initial Blood Pressure rise (3 sec)→ sympathetic transient activation
- 2) Stand up (7 sec)→ Blood Pressure fall
- 3) Overshoot → sympathetic activation / Inibithion of parasimpathetic output
- 4) Blood Pressure stabilitation
- 5) Gradual blood pressure and heart rate increase




#### **Tilt Table Testing**

Systolic blood pressure

**Heart Rate** 

Diastolic blood pressure





The table is tilted up laying  $\rightarrow$  70°



The table is tilted down 70° → laying



#### Orthostatic Hypotension (OH)

Head-up tilt (HUT): BP fall ≥ 20 mmHg (systolic) and/or 10 mmHg (diastolic) within 3 minutes of standing or HUT to at least 60°. Some Authors advocate for a BP fall threshold of 30/15 mmHg if supine hypertension is present or to fulfill MSA diagnostic criteria.

Sit-to stand test: technically simpler test than standard HUT, with screening purposes; the diagnostic threshold of BP drop is ≥ 15 mmHg (systolic) and/or 7 mmHg (diastolic).

Initial OH: BP fall ≥ 40/20 mmHg within 15 seconds of active standing. No clear pathologic meaning, but it can lead to orthostatic symptoms or syncope. Detectable with beat-to-beat technology only.

Delayed OH: OH ensuing after 3 minutes of upright standing, up to 10-30 minutes after standing. Represents a milder degree of autonomic failure and can mimic vaso-vagal syncope.




#### **Tilt Table Testing**

Systolic blood pressure

**Heart Rate** 

Diastolic blood pressure







The table is tilted up laying  $\rightarrow$  70°

The table is tilted down 70° → laying

#### Pathological Alterations in the Baroreflex



#### **Abnormalities in the Circadian Rythm**



#### Neurogenic vs. Non-Neurogenic OH

OH can be distinguished in:

- a) Neurogenic (nOH) → Cardiovascular autonomic neuropathy
- b) Non-neurogenic OH → Dehydration, hypovolemia, cardiac pump failure, and venous pooling

In nOH the expected compensatory heart rate (HR) increase is reduced.

Suggested cut-off to support the diagnosis of nOH:

- -Standing HR increase < 15 bpm in the presence of OH.
- $-\Delta$ HR/  $\Delta$  SBP ratio < 0.5 bpm/mmHg




## Orthostatic hypotension in Parkinson Disease: Impact on Health Care Utilization

Healthcare utilization cost in United States Dollars per patient per year.

	PD-OH+	PD-OH-	P-value
	(n = 93)	(n = 224)	
Hospitalizations	\$22,813 ± \$6280	\$7995 ± \$4001	0.038
ER visits	$1425 \pm 426$	\$911 ± \$302	0.044
Outpatients visits	$\$863 \pm \$61$	\$852 ± \$47	0.854
Telephone calls/e-mails	$$62 \pm $7$	$$39 \pm $5$	0.006
TOTAL	$25,205 \pm 6546$	\$9831 ± \$4167	0.037

#### **Orthostatic Hypotension: Therapies**



#### **Supine Hypertension: Definitions**

Mild SH= Systolic ≥140 mmHg e/o Diastolic ≥90 mmHg after 5 or more minutes of supine resting

**Moderate SH**= Systolic ≥160 mmHg e/o Diastolic ≥100 mmHg after 5 or more minutes of supine resting

**Severe SH**= Systolic ≥180 mmHg e/o Diastolic ≥110 mmHg after 5 or more minutes of supine resting

#### Pharmacological Therapies for Supine Hypertension


- Captopril 25 mg
- Clonidine 0.1 mg (risk of "awakening hypotension")
- Hydralazine 10-25 mg
- Losartan 50 mg
- Nitroglycerine patch 0.1 mg/h



#### Impact of Pharmacological Therapy

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension

Phase 3, randomized, placebo controlled, double-blind study 225 PD, non-demented patients with OH





### POTS – Postural Orthostatic Tachycardia Syndrome

Heart rate increment of ≥30 bpm within 10 min of standing or head-up tilt associated with lightheadedness, palpitations, sweating, or tremulousness, relieved by recumbency. Standing heart rate is often ≥120 bpm.

- 1. Neuropathic POTS (small orthostatic decrease of BP, not fulfilling OH criteria, reduced leg sweating) → <u>vasoconstrictor (α1 agonists,</u> <u>droxidopa)</u>
- 2. Hyperadrenergic POTS (orthostatic BP increase with elevated plasma norepinephrine)  $\rightarrow \beta$ -blockers, clonidine, ivabradine
- 3. Deconditioned/Hypovolemic POTS (orthostatic reduction in pulse pressure, consequent to physical deconditioning or inadequate sodium and fluid intake) → <u>fludrocortisone</u>, <u>water</u>, <u>and salt</u>




#### **Tilt Table Testing**

\_\_\_\_

Systolic blood pressure

**Heart Rate** 

Diastolic blood pressure





The table is tilted up laying  $\rightarrow$  70°



#### **Neurally mediated (reflex) syncope**

Sudden change in autonomic nervous system activity that leads to a fall in cerebral perfusion with **cardiodepressive**, **vasodepressive**, or **mixed** components.

Reflex syncope encompasses:


- a) Vasovagal syncope: triggered by orthostasis, emotions, or pain
- b) Situational syncope: triggered by micturition, cough, or other visceral stimuli
- c) Carotid Sinus Hypersensitivity: triggered by hypersensitivity of the carotid sinus baroreceptors


Neurally mediate syncopes **must be distinguished** from nOH-associated syncopes, in which the reduced cerebral perfusion is due to cardiovascular autonomic neuropathy




	MSA	PD	PAF
TYPE OF a-SYNUCLEIN DEPOSITS	Major glial cytoplasmic inclusions	Lewy bodies	Lewy bodies
SITE OF a-SYNUCLEIN DEPOSITS	CNS	CNS and PNS	Mostly PNS
ONUF NUCLEUS (segments S2-S4 of the spinal cord)	Degeneration	Normal	Normal
CARDIAC POSTGANGLIONIC SYMPATHETIC FIBERS	Not affected	Affected	Affected
SUDOMOTOR FIBERS	Involvement of preganglionic and postganglionic fibers	Length-dependent involvement of postganglionic fibers	Involvement of postganglionic fibers
AUTONOMIC SKIN NERVE FIBERS	Only one report of p-a- Syn deposition in dermal nerve fibers	P-a-Syn inclusions	P-a-Syn inclusions












**MSA – Taupaties – Normal** 





Parkinson - DLB - PAF




### Survival in synucleinopathies


A prospective cohort study











"SYNERGISTIC IMPACT"





